prev next front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |24 |25 |26 |27 |28 |29 |30 |31 |32 |review
Another preventive therapy that seems to impact upon CRP is hormone-replacement therapy (HRT). The Postmenopausal Estrogen/Progestin Interventions (PEPI) study randomized postmenopausal women to placebo or to four different estrogen or estrogen plus progesterone regimens: conjugated equine estrogens (CEE) 0.625 mg/d, CEE 0.625 mg/d plus medroxyprogesterone acetate (MPA) 10 mg/d for days 112 each month (cyclic), CEE 0.625 mg/d plus MPA 2.5 mg/d (continuous), or CEE plus micronized progesterone (MP) 200 mg/d, days 112 each calendar month. Regardless of the HRT preparation, CRP levels markedly increased following initiation of HRT. These data have been confirmed elsewhere and have raised the possibility that part of the early thrombotic hazard that might be associated with initiation of HRT may relate in some way to a proinflammatory effect. 

Reference:
Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, Sakkinen PA, Tracy RP. Effect of postmenopausal hormones on inflammation?sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999;100:717-722.
Web site